Fennec Pharmaceuticals (FENC) Aktienübersicht
Fennec Pharmaceuticals Inc. ist ein biopharmazeutisches Unternehmen im kommerziellen Stadium in den Vereinigten Staaten. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 6/6 |
| Künftiges Wachstum | 5/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
FENC Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Fennec Pharmaceuticals Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$10.70 |
| 52-Wochen-Hoch | US$11.31 |
| 52-Wochen-Tief | US$5.65 |
| Beta | 1.07 |
| 1 Monat Veränderung | 22.99% |
| 3 Monate Veränderung | 66.67% |
| 1 Jahr Veränderung | 21.59% |
| 3 Jahre Veränderung | 20.50% |
| 5 Jahre Veränderung | 61.39% |
| Veränderung seit IPO | -90.56% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jun 15
FENC: Expanding Cisplatin Tumor Coverage Will Support Future Bullish Earnings Multiple
Analysts have raised their price target on Fennec Pharmaceuticals to $16 from $13, citing growing Pedmark adoption across new and existing accounts, with demand coming from three core tumor types. What's in the News Four PEDMARK clinical abstracts accepted for presentation at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, focusing on multiple tumor types and age groups.Narrativ-Update • Jun 01
FENC: Expanding Cisplatin Cancer Use Will Support Future Bullish Earnings Multiple
Analysts have lifted their price target on Fennec Pharmaceuticals stock to $16 from $13, pointing to building Pedmark adoption across core tumor types, including testicular, cervical, and head and neck cancers, as the key driver behind the change. What's in the News Four new PEDMARK abstracts have been accepted for presentation at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, focusing on multiple tumor types and patient populations.Analyseartikel • May 17
We're Not Worried About Fennec Pharmaceuticals' (NASDAQ:FENC) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Recent updates
Narrativ-Update • Jun 15
FENC: Expanding Cisplatin Tumor Coverage Will Support Future Bullish Earnings Multiple
Analysts have raised their price target on Fennec Pharmaceuticals to $16 from $13, citing growing Pedmark adoption across new and existing accounts, with demand coming from three core tumor types. What's in the News Four PEDMARK clinical abstracts accepted for presentation at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, focusing on multiple tumor types and age groups.Narrativ-Update • Jun 01
FENC: Expanding Cisplatin Cancer Use Will Support Future Bullish Earnings Multiple
Analysts have lifted their price target on Fennec Pharmaceuticals stock to $16 from $13, pointing to building Pedmark adoption across core tumor types, including testicular, cervical, and head and neck cancers, as the key driver behind the change. What's in the News Four new PEDMARK abstracts have been accepted for presentation at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, focusing on multiple tumor types and patient populations.Analyseartikel • May 17
We're Not Worried About Fennec Pharmaceuticals' (NASDAQ:FENC) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Narrativ-Update • May 14
FENC: Expanding Cisplatin Ototoxicity Protection Use Will Support Future Bullish Earnings Multiple
Analysts have maintained their $18.00 price target on Fennec Pharmaceuticals, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that leave their overall valuation view unchanged. What's in the News Four abstracts on PEDMARK are set to be presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, focusing on cisplatin related hearing loss and real world outcomes in patients receiving platinum based chemotherapy (Key Developments).Narrativ-Update • Apr 25
FENC: Expanding Cisplatin Ototoxicity Use Should Support Future Bullish Earnings Multiple
Analysts have adjusted their price target on Fennec Pharmaceuticals to $18.00, with the change supported by updated assumptions around revenue growth, profit margins, and a future P/E of about 12.8, in line with a recently bullish initiation from Street research. Analyst Commentary Bullish analysts are framing the updated US$18.00 price target as consistent with expectations for Fennec Pharmaceuticals to execute against current revenue and margin assumptions while trading on a P/E of about 12.8. These views generally point to a setup where, if the company delivers on its plan, the current valuation case remains intact and could support the new target level.Narrativ-Update • Apr 10
FENC: Cisplatin Ototoxicity Niche Will Support Future Bullish Earnings Multiple
Analysts have raised their price target on Fennec Pharmaceuticals to $18.00, supported by updated assumptions on revenue growth, profit margin and future P/E, and underpinned by a recent bullish initiation from B. Riley that reflects growing confidence in the company’s outlook.Narrativ-Update • Mar 27
FENC: Cisplatin Ototoxicity Niche Will Underpin Future Supportive Care Upside
Analysts have reaffirmed an $18 price target for Fennec Pharmaceuticals, highlighting supportive research that emphasizes Pedmark's role as a unique, approved option in oncology supportive care. They are also reassessing assumptions related to future revenue growth, profit margins and P/E expectations.
Narrativ-Update • Mar 11
FENC: Single Oncology Supportive Care Asset Will Drive Future Upside Potential
Narrative Update: Fennec Pharmaceuticals Analysts have lifted their price target on Fennec Pharmaceuticals from $14.00 to about $15.33, citing a richer revenue outlook, higher anticipated profit margins, and a willingness to apply a lower future P/E multiple. They highlight Pedmark's position as a unique, FDA approved option in oncology supportive care, with U.S. peak sales potential referenced above $300m.Narrativ-Update • Feb 25
FENC: Cisplatin Ototoxicity Niche Will Support Future Oncology Care Upside
Analysts are reiterating an $18 price target for Fennec Pharmaceuticals. They point to updated assumptions that include slightly lower discount rates, higher projected revenue growth and profit margins, and a modestly lower future P/E, supported by recent bullish initiations that highlight Pedmark's role as a unique oncology supportive care opportunity.Narrativ-Update • Feb 10
FENC: Cisplatin Ototoxicity Niche Will Drive Future Supportive Care Upside
Analysts have reiterated a US$18 price target on Fennec Pharmaceuticals, supported by their view that Pedmark offers a unique, only-approved option in oncology supportive care, with what they describe as realistic peak U.S. sales potential above US$300m. Analyst Commentary Recent coverage has centered on Pedmark as a key driver for Fennec's equity story, with bullish analysts highlighting its role as the only approved agent for reducing the risk of cisplatin induced ototoxicity in oncology supportive care.Narrativ-Update • Jan 26
FENC: Cisplatin Ototoxicity Leadership And New Studies Will Support Strong Future Upside
Narrative Update Analysts are reaffirming a US$18 price target on Fennec Pharmaceuticals, pointing to Pedmark's role as the only approved agent for reducing cisplatin induced ototoxicity and noting that they view U.S. peak sales potential above US$300m as realistic. Analyst Commentary Bullish analysts are highlighting Fennec Pharmaceuticals as a focused oncology supportive care story, built around Pedmark as an intravenous formulation of sodium thiosulfate for reducing the risk of cisplatin induced ototoxicity.Narrativ-Update • Jan 12
FENC: Unique Oncology Supportive Care Opportunity Will Drive Stronger Future Upside Potential
Narrative Update Overview Our fair value estimate for Fennec Pharmaceuticals edges up from $17 to $18 per share, reflecting analysts' view that Pedmark offers a unique oncology supportive care opportunity with U.S. peak sales potential cited north of $300 million and supports using a slightly higher revenue growth outlook, modestly stronger profit margins, and a lower future P/E multiple. Analyst Commentary Bullish analysts are centering their thesis on Pedmark as a differentiated oncology supportive care product, and that view is shaping how they think about valuation, execution risk, and long term growth potential.Narrativ-Update • Dec 27
FENC: Expanded Adult Study Will Drive Stronger Future Upside Potential
Analysts have nudged their price target on Fennec Pharmaceuticals modestly higher to reflect slightly faster expected revenue growth, marginally improved profit margins, and a marginally lower projected future price to earnings multiple, supporting a fair value estimate of $17.00 per share. What's in the News Planned City of Hope investigator sponsored study will evaluate PEDMARK for preventing cisplatin induced hearing loss in adult men with stage II III metastatic testicular germ cell tumors, expanding its potential use beyond pediatrics (company announcement).Seeking Alpha • Dec 22
Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026
Summary Fennec Pharmaceuticals is a commercial-stage oncology supportive-care company centered on Pedmark/Pedmarqsi. This drug helps reduce cisplatin-induced ototoxicity in pediatric patients who are battling cancer. Pedmark is FDA-approved for pediatric patients ≥1 month, and it has shown good efficacy so far with patients. Pedmark is also the “first/only” in this drug class, and management believes they can eventually make Pedmark the standard-of-care to avoid hearing loss. Thus, despite FENC’s concentrated risk on Pedmark, I feel their outlook for 2026 is quite compelling. So, I rate the stock a “Buy” at these levels. Read the full article on Seeking AlphaNarrativ-Update • Dec 13
FENC: Expanded Hearing Loss Indication Will Drive Stronger Future Upside Potential
Analysts have raised their price target on Fennec Pharmaceuticals from 15 dollars to 17 dollars, citing updated assumptions for discount rates, growth, profitability, and valuation multiples that, despite being more conservative on margins and revenue growth, still imply a higher fair value. What's in the News City of Hope to launch an investigator sponsored study of PEDMARK in adult men with stage II III metastatic testicular germ cell tumors to prevent cisplatin induced hearing loss, expanding potential use beyond pediatrics (company announcement) Positive topline results reported from the Phase 2/3 STS J01 trial in Japan evaluating PEDMARK for reducing cisplatin induced ototoxicity in pediatric and AYA patients, with Fennec planning to pursue Japanese registration and potential partnering or licensing deals (company announcement) Completed 35 million dollar follow on equity offering of 4,666,667 common shares at 7.50 dollars per share, bolstering the balance sheet for commercialization and development initiatives (financing filing) Announced a non brokered private placement of 670,000 common shares at 7.50 dollars per share for expected gross proceeds of 5.0 million dollars, with closing targeted for November 17, 2025 (financing announcement) Lock up agreements put in place on over 28 million common shares and various equity linked awards through February 12, 2026, limiting insider and holder sales for 91 days after the November 13, 2025 offering (offering documentation) Valuation Changes Fair value estimate increased from 15 dollars to 17 dollars per share, implying a modest upward revision to intrinsic value despite more conservative operating assumptions.Analyseartikel • Apr 24
Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price Is Matching Sentiment Around Its Revenues
With a price-to-sales (or "P/S") ratio of 3.3x Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) may be sending very bullish...Analyseartikel • Mar 13
US$12.60: That's What Analysts Think Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Is Worth After Its Latest Results
Shareholders might have noticed that Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) filed its full-year result this time...Analyseartikel • Nov 24
Improved Revenues Required Before Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Stock's 25% Jump Looks Justified
Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) shareholders are no doubt pleased to see that the share price has bounced...Analyseartikel • Oct 04
Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price
You may think that with a price-to-sales (or "P/S") ratio of 2.5x Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) is...
Neues Narrativ • Sep 28
Jeff Hackman's Leadership And PEDMARK's Launch Promise Robust Revenue Surge
Introduction of PEDMARK and strategic partnerships aim to boost net revenues through expanded patient access and improved distribution.Analyseartikel • Aug 15
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be
Today is shaping up negative for Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) shareholders, with the analysts delivering...Analyseartikel • Jul 16
Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Jun 02
Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop
The Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) share price has fared very poorly over the last month, falling by a...Aktionärsrenditen
| FENC | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -2.9% | 4.1% | 1.6% |
| 1Y | 21.6% | 41.1% | 18.6% |
Rendite im Vergleich zur Industrie: FENC unter dem Niveau der Branche US Biotechs , die im vergangenen Jahr eine Rendite von 41.1% erzielte.
Rendite vs. Markt: FENC übertraf den Markt US, der im vergangenen Jahr eine Rendite von 18.6 erzielte.
Preisvolatilität
| FENC volatility | |
|---|---|
| FENC Average Weekly Movement | 12.7% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: Der Aktienkurs von FENC war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.
Volatilität im Zeitverlauf: FENCDie wöchentliche Volatilität (13%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1996 | 35 | Jeff Hackman | www.fennecpharma.com |
Fennec Pharmaceuticals Inc. ist ein biopharmazeutisches Unternehmen in den Vereinigten Staaten, das sich im kommerziellen Stadium befindet. Zu den Produktkandidaten des Unternehmens gehört PEDMARK, eine Formulierung von Natriumthiosulfat zur Vorbeugung von Cisplatin-induzierter Ototoxizität bei pädiatrischen Patienten. Das Unternehmen vertreibt seine Produkte über regionale Fachärzte für pädiatrische Onkologie und medizinisch-wissenschaftliche Kontaktpersonen.
Fennec Pharmaceuticals Inc.'s Grundlagenzusammenfassung
| FENC grundlegende Statistiken | |
|---|---|
| Marktanteil | US$371.69m |
| Gewinn(TTM) | -US$8.37m |
| Umsatz(TTM) | US$51.00m |
7.3x
Kurs-Umsatz-Verhältnis-44.4x
Kurs-Gewinn-Verhältnis Ist FENC zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| FENC Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$51.00m |
| Kosten der Einnahmen | US$3.96m |
| Bruttogewinn | US$47.04m |
| Sonstige Ausgaben | US$55.41m |
| Gewinn | -US$8.37m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.24 |
| Bruttomarge | 92.23% |
| Nettogewinnspanne | -16.42% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich FENC auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/05 22:24 |
| Aktienkurs zum Tagesende | 2026/07/02 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Fennec Pharmaceuticals Inc. wird von 10 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Naureen Quibria | Capital One Securities, Inc. |